People considering weight-loss medications might wonder which one works best, and first-of-its-kind research points to an answer. A new study published in the New England Journal of Medicine ...

But it’s worth mentioning that when Wegovy was tested at a much higher dose of 7.2 milligrams, people lost around 20.7% of their body weight. That’s a big jump from the 13.7% seen with the ...

Researchers explained in the study that weight loss was about 6% lower in men than in women in both groups, but trial participants in both groups lost more weight, and experienced improvements in ...

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA. Results from the phase 3b STEP UP ...

Nearly 32% of Zepbound users ultimately lost at least a quarter of their body weight, compared with just 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women.

As India becomes the new and latest nation witnessing the for weight-loss drugs frenzy, Novo Nordisk’s Wegovy challenges Eli Lilly’s Mounjaro in a high-stakes obesity treatment challenge.

In key secondary endpoints, Zepbound was superior across all weight reduction targets with 64.6% of participants treated with Zepbound achieving at least 15.0% weight loss compared to 40.1% on Wegovy.

Study compares effectiveness of popular weight loss drugs 02:38. Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known ...

Trial reveals if Zepbound or Wegovy is better for weight loss Why you should care: People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.